Navigation Links
Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
Date:8/5/2008

t expenses, sales, marketing and distribution expenses, and general and administrative expenses, based on the nature of the work the Company's employees were assigned to perform, totaled RMB6.4 million (US$0.9 million) for the second quarter of 2008. The share-based compensation expenses for the second quarter of 2007 were RMB7.7 million. For the first six months of 2008, share-based compensation expenses totaled RMB13.4 million (US$2.0 million), a decrease of 7.5% from RMB14.5 million for the first six months of 2007.

Operating income was RMB98.1 million (US$14.3 million) for the second quarter of 2008, representing an increase of 73.9% as compared to RMB56.4 million for the corresponding period of 2007. For the first six months of 2008, operating income was RMB197.3 million (US$28.8 million), an increase of 51.3% as compared to RMB130.5 million in the corresponding period in 2007.

Income tax expense for the second quarter of 2008 totaled RMB18.1 million (US$2.6 million) compared to an income tax credit of RMB4.0 million for the corresponding period of 2007. For the first six months of 2008, income tax expense was RMB34.9 million (US$5.1 million) compared to an income tax credit of RMB2.5 million for the first six months of 2007. In addition to the overall increase in taxable income, the increased income tax expense in 2008 was primarily due to the expiration of tax holidays enjoyed by two PRC subsidiaries.

Net income was RMB95.2 million (US$13.9 million) for the second quarter of 2008, compared to RMB83.1 million in the corresponding period a year ago and representing growth of 14.5%. The Company's net margin (net income as a percentage of total revenue) was 21.8% for the second quarter of 2008 compared to 24.9% for the second quarter of 2007. For the first six months of 2008, net income was RMB207.3 million (US$30.2 million), an increase of 38.1% as compared to RMB150.1 million for the first six months of 2007. Net margin for the first six mo
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
3. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
4. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
7. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
8. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
9. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... SafeHandles™ announced that they will be ... Begley Jr, airing via Discovery Channel. Dates and show ... passive, non-invasive, replaceable, and affordable germ protective device. This ... sleeves and adhesives to promote hand hygiene in high ... of SafeHandles is the desire to make a positive ...
(Date:11/24/2014)... 24, 2014 "My friend was killed ... to cross the street in his motorized wheelchair," said ... him. I came up with this idea so that ... , He developed the Safety Lites to make a ... conditions. The device ensures that motorists can see the ...
(Date:11/23/2014)... November 23, 2014 The report, ... 2006 to 2020 - Asia-Pacific” provides quantitative analysis ... market segments: minimally invasive body contouring devices, non-invasive ... analysis includes market size data by revenue and ... following countries: China, Japan, South Korea, Australia and ...
(Date:11/23/2014)... friends have more influence on teens, alcohol use than ... "We,ve known for a long time that ... use, but there are no common studies that distinguished ... influence on those decisions," Jonathon Beckmeyer, an assistant professor ... a university news release. Beckmeyer analyzed data gathered ...
(Date:11/23/2014)... show thanks to new and old customers, iFitDress.com has ... for weddings. Customers who need custom outfits can talk ... dress manufacturer, and it is among the ones which have ... long time. The CEO of this company says, "iFitDress.com is ... buy not only a beautiful dress, but also a piece ...
Breaking Medicine News(10 mins):Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Close Friends May Be Key to Teens' Drinking 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
... Demonstrates a 20-Meter Improvement in Six-Minute Walk ... Distance ... Time on November 1, 2007, SILVER SPRING, Md., Nov. 1 ... Rx, Inc., announced today the completion of their TRIUMPH-1 Phase 3,trial ...
... Calif., and WHITEHOUSE STATION, N.J., Nov. 1, Dynavax ... Co., Inc. (NYSE: MRK ) today announced ... develop HEPLISAV(TM), a,novel investigational hepatitis B vaccine, which ... clinical trial involving adults and in,patients on dialysis. ...
... 1 The makers of the WaveSense line ... Claudio,Carboni, formerly of Menarini Diagnostics, has joined as ... WaveSense Europe will,distribute the company,s high accuracy, WaveSense ... market both directly and through local,partners. Carboni ...
... Upload Video Confessions/ Testimonials for ... PHILADELPHIA and LONDON, Nov. 1 Thomson,Scientific, ... ; TSX: TOC) and,leading provider of information solutions ... the launch of its new campaign,"Confessions ... of ...
... (MHS), a not-for-profit health care system with hospitals ... it has selected,Integrated Healthcare Holdings, Inc. (IHHI) to ... partially physician-owned publicly traded hospital management,company, owns and ... total of,770 beds, 2787 employees and 1725 active ...
... Oct. 31 Always Best Care Senior,Services has expanded ... Living Placement Service, and Personal Response Company, is,proud to ... Always Best Care,Senior Services for outstanding care. For over ... our work - a sincere concern for,the betterment of ...
Cached Medicine News:Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 2Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 3Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 4Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 5Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 6Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 2Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 3Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 4Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 5Health News:Ex-Head of Menarini Diabetes Unit Launches WaveSense Europe 2Health News:Thomson Scientific Launches 'Confessions ... of a User' Campaign Asking 'Are You the New Face of Research?' 2Health News:Memorial Health Services Announces Sale of Anaheim Memorial Medical Center 2Health News:Announcing Always Best Care Senior Services Expansion Into San Diego, California 2
(Date:11/24/2014)... , Nov. 24, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the Piper ... 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ... New York . A live audio webcast ... section of Arena,s website at www.arenapharm.com . A replay ...
(Date:11/24/2014)... 24, 2014 Luoxis Diagnostics, Inc., a ... today announced the presentation of three clinical and ... a broadly applicable and robust research tool capable ... in response to injury, illness, or stress.  In ... with Luoxis, academic and pharmaceutical research partners, RedoxSYS ...
(Date:11/24/2014)... The Female Health Company (NASDAQ-CM: FHCO), today ... to discuss its operating results for the fourth quarter ... December 2, 2014 at 11:00 a.m. Eastern Standard Time ... earlier the same day. Shareholders and other ... dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2
... SAN FRANCISCO, Calif., May 16, 2011 diaDexus, Inc. (OTC ... on the development and commercialization of patent-protected in vitro ... announced financial results for the first quarter of 2011. ... were $3.3 million, representing 25% growth over total revenues of ...
... Oncology molecules in development will be presented during the 47th ... held in Chicago, Ill. from June 3 – 7, 2011. ... industry, with more than 30 molecules in development to treat ... these pipeline molecules are being evaluated for certain biomarkers or ...
Cached Medicine Technology:diaDexus, Inc. Reports 2011 First Quarter Financial Results 2diaDexus, Inc. Reports 2011 First Quarter Financial Results 3diaDexus, Inc. Reports 2011 First Quarter Financial Results 4diaDexus, Inc. Reports 2011 First Quarter Financial Results 5Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011 2Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011 3
TBR-720-2-GD is large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standard AS38...
... direct competitive EIA for the quantitative ... or plasma. A specific agent displaces ... available for antibody binding. Testosterone then ... to fluorescein isothiocyanate (FITC) and alkaline ...
... Testosterone, (17-Hydroxy-4-androstene-3-one), a C19 steroid, is one ... [1]. In postpubertal males, testosterone is secreted ... small amount derived from peripheral conversion of ... been estimated that over 50% of serum ...
... testosterone exists as unbound or free testosterone. ... SHBG with high affinity [1], while the ... the albumin-bound and free fractions may be ... action. Measurement of the free or unbound ...
Medicine Products: